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ABSTRACT 
 
The antifolate combination of sulfadoxine and pyrimethamine (SP) is one of few 
remaining affordable drug combinations available for wide-scale treatment of 
uncomplicated Plasmodium falciparum malaria in Africa. In vivo studies of SP 
efficacy conducted during 1998, 2000 and 2002 at the Naas sentinel site in 
Mpumalanga province, South Africa, demonstrated a gradual non-significant increase 
in late treatment failure (LTF) and early treatment failure (ETF) resistance to SP, 
while gametocyte carriage increased significantly between 1998 and 2002 (p < 
0.0001). This study aimed to determined and compare the frequency of dihydrofolate 
reductase (dhfr) and dihydropteroate synthetase (dhps) resistant haplotypes in P. 
falciparum parasites from patients treated with SP in three consecutive standardized 
in vivo therapeutic efficacy studies in Mpumalanga province, since implementation of 
SP as first line treatment in 1998, and to investigate associations between the presence 
of mutations and treatment outcomes after SP treatment. Four hundred-and-three 
samples were studied and 358 yielded polymerase chain reaction products. A novel 
high throughput sequence-specific oligonucleotide probe-based approach was used to 
examine the resistance status of the three in vivo P. falciparum populations. Screening 
for the presence of all known point mutations in dhfr and dhps genes revealed that 
only five dhfr and three dhps allelic haplotypes were present. In all the samples 
investigated, point mutations were identified only at codons 108, 51 and 59 of the dhfr 
gene and at codons 347 and 540 of the dhps gene. The prevalence of dhfr resistant 
haplotypes was 35.4% in 1998, 38.7% in 2000, and 41.0% in 2002, while the 
prevalence of dhps resistant haplotypes was 9.7% in 1998, 7.2% in 2000 and 41.6% in 
2002, the latter representing a significant increase (p < 0.002). The prevalence in both 
dhfr and dhps gene resistant haplotypes were selected gradually during the three in 
vivo studies in Mpumalanga province. Infection with parasites having triple dhfr 
mutations and double dhps mutations, "the quintuple mutant", was associated with SP 
treatment failure (p < 0.001). Mutations at both dhfr and dhps loci may be important 
predictors of SP resistance in Mpumalanga province. 
 
